2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.
Zeynep Eroglu, MD, medical oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center, assistant professor, Department of Oncologic Sciences, the University of South Florida, Morsani College of Medicine, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.
In a retrospective cohort analysis, investigators evaluated the association between baseline metastatic patterns and clinical outcomes in patients with BRAF-mutant metastatic melanoma. Combination immunotherapy is commonly used in metastatic melanoma, and BRAF/MEK inhibitors represent treatment options as targeted therapy, Eroglu says. This retrospective cohort analysis investigated real-world data from patients who were treated at a number of community centers across the United States, Eroglu adds.
Investigators also looked at changes regarding sites of distant metastases and the overall number of metastases to see how that correlated with outcomes for patients, Eroglu concludes.